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1. Introduction 
Dyspnea is a complex sensation involving interaction of physiological, psychological, 
social, and environmental factors. Dyspnea in general is common across cardio-vascular 
and respiratory conditions and it is often difficult to clinically differentiate the exact cause 
of dyspnea in patients with heart or lung disease. Pulmonary hypertension in the absence 
of heart or lung disease, a condition called pulmonary arterial hypertension (PAH), is due 
to endothelial dysfunction and remodelling of small pulmonary arteries. Progressive 
dyspnea on exertion is a cardinal sign of PAH, which is often first diagnosed when in 
advanced stages. Improved understanding of pathogenic mechanisms underlying PAH 
and the related dyspnea should translate into new treatment options for symptom control 
and to prevent disease progression. This chapter reviews the current understanding of the 
etiology and pathogenesis of PAH and recent advances in management of this debilitating 
condition. 
2. Pulmonary hypertension: Definition, classification and assessment of 
severity 
Pulmonary hypertension was first described by Ernst von Romberg (von Romberg, 1891) 
and manifests as an increase in blood pressure in the pulmonary artery, vein, or capillaries. 
Elevated pulmonary vascular resistance and pressure lead to dyspnea, dizziness and 
fainting, all of which are exacerbated by exertion. Pulmonary hypertension leads to a 
progressive decrease in exercise tolerance, and ultimately to heart failure, with a median life 
expectancy from diagnosis of only 2.8 years. Pulmonary hypertension was previously 
defined as a mean pulmonary arterial pressure of 25 mmHg or more at rest, and/or 30 
mmHg or more on light to moderate exercise. However, this definition has recently been 
revised with the exercise criterion in the previous definition being removed due to the 
difficulty of defining an exact upper limit of normal for pulmonary pressures during 
exercise. According to the most recent Dana Point revised classification (Simonneau et al., 
2009; Galiè et al., 2009b), pulmonary hypertension is classified into five major groups: 1) 
pulmonary arterial hypertension (PAH), 2) pulmonary hypertension due to left heart 
disease, 3) pulmonary hypertension due to chronic lung disease and/or hypoxia, 4) 
pulmonary hypertension due to chronic thromboembolic disease and 5) pulmonary 
hypertension with unclear or multifactorial etiologies (Table 1). 
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Table 1.Classification of Pulmonary Hypertension 
PAH is defined by a mean pulmonary arterial pressure at rest equal or greater than 25 mm 
Hg in the presence of a normal pulmonary capillary wedge pressure (< 15 mm Hg) and 
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forms a distinct subgroup of pulmonary hypertension. PAH incorporates a number of 
different groups including familial/heritable PAH, idiopathic PAH and PAH associated 
with connective tissue disease, congenital heart disease, portal hypertension, or human 
immuno-deficiency virus (HIV) infection. Clinical severity of PAH is expressed in World 
Health Organisation (WHO) functional classes (FC), which mainly describe the severity of 
dyspnea experienced by patient (Barst et al., 2004) (Table 2). Assessment of severity is 
important as it guides clinical management and helps to determine prognosis (D’Alonzo 
et al., 1991). In untreated patients with PAH, historical data showed a median survival of 
6 years for WHO-FC I and II, 2.5 years for WHO-FC III, and just 6 months for WHO-FC IV 
(D’Alonzo et al., 1991). Extremes of age (<14 yrs or >65 yrs), falling exercise capacity, 
syncope, haemoptysis and signs of RV failure all confer a worse prognosis in PAH. 
Patients with PAH in WHO-FC III or IV benefit from specific disease-modifying 
treatments and data to support improved outcomes from treatment of earlier stages of 
PAH are emerging.  
 
Class Symptomatic profile 
 
Class I Patients with pulmonary hypertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause dyspnea or 
fatigue, chest pain or near syncope 
 
Class II Patients with pulmonary hypertension resulting in slight limitation of 
physical activity. They are comfortable at rest. Ordinary physical activity 
causes undue dyspnea or fatigue, chest pain or near syncope 
 
Class III Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity 
causes undue dyspnea or fatigue, chest pain or near syncope 
 
Class IV Patients with pulmonary hypertension with inability to carry out any 
physical activity without symptoms. These patients manifest signs of 
right heart failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
Table 2. WHO Classification of functional status of patients with pulmonary hypertension 
3. Dyspnea and exercise intolerance in pulmonary arterial hypertension 
Dyspnea is a complex sensation comprising at least three distinct sensations including air 
hunger, work/effort, and chest tightness. Dyspnea on exertion is a hallmark of PAH. The 
mechanism of dyspnea in pulmonary hypertension is complex and depends on the 
underlying condition and co-morbidities. It has been hypothesised that in pulmonary 
hypertension associated with pulmonary thromboembolism pressure, receptors or C fibers 
in the pulmonary vasculature or right atrium mediate the sensation of dyspnea (Manning & 
Schwartzstein, 1995). This mechanism may also operate in PAH since the severity of 
dyspnea in these patients is disproportionate to the impairment of left ventricular function, 
respiratory mechanics and gas exchange. In PAH dyspnea on exertion is usually associated 
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with little or no abnormalities in lung mechanics measured at rest (e.g., normal spirometry 
and lung volumes), while lung gas exchange may be abnormal (e.g., reduced diffusing lung 
capacity for carbon monoxide (DLco) (Chandra et al., 2010). Therefore, it is likely that 
exertional dyspnea in PAH results from complex interactions of signals from the central 
nervous system (i.e. autonomic centers in the brain stem and the motor cortex) and receptors 
in the upper airway, lungs, right atrium, pulmonary vessels and chest wall (Manning et al., 
1995; O’Donnell et al, 2009). Cardiopulmonary exercise testing (CPET), which measures 
pulmonary gas exchange during exercise, demonstrates significant oxygen transport 
abnormalities, such as a decrease in peak oxygen uptake (V’O2), a decreased slope of the 
increase in V’O2-work rate relationship and a low lactic threshold (Palange et al, 2007). In 
addition, patients with PAH often have a low V’E and a normal breathing reserve at peak 
exercise. This reflects the fixed high physiological dead space consequent to reduced 
pulmonary perfusion. The alveolar-arterial O2 difference is often widened during exercise; a 
right-to-left shunt may contribute to arterial hypoxemia during exercise in a proportion of 
patients with co-existent patent foramen ovale. Excessive V’E at low absolute work rates 
may also reflect the influence of a premature lactic academia. Finally, the breathing 
pattern tends to be more rapid and shallow than normal; this pattern is not explained by 
restrictive mechanics and may result from activation of vagal-innervated 
mechanoreceptors in the right atrium, pulmonary vasculature and pulmonary 
interstitium. Importantly, with CPET it is possible to detect an abnormal increase in 
exercise ventilatory response relative to carbon dioxide output (V’E/V’CO2) that is 
associated with a proportional and sustained reduction in end-tidal carbon dioxide partial 
pressure (PETCO2) (Riley et al., 2000). The degree of ventilatory and gas exchange 
inefficiency during exercise (i.e., the increase in V’E/V’CO2 and the drop in PETCO2) 
correlates with the severity of the disease, and the level of PETCO2 reduction may be a 
useful non-invasive screening tool for the selection of PAH patients for right heart 
catheterization (Yasunoby et al., 2005). Interestingly, differences in ventilatory and gas 
exchange adaptations to cycling and walking exercise have been described in PAH; 
walking, in particular, is more severely limited by high ventilatory response, arterial O2 
desaturation and dyspnea sensation compared to cycling (Valli et al., 2008).  
Right heart catheterization with measurement of pulmonary artery pressure and cardiac 
output has traditionally been used to assess the severity of PAH and the response to 
interventions. However, catheterization is invasive and cumbersome, largely restricted to 
tertiary referral centers and not suitable for regular follow-up. Therefore, exercise testing has 
been used in its place as a surrogate marker to monitor disease severity and prognosis. 
Wensel et al. studied the prognostic value of V’O2 peak in patients with PAH and reported 
that patients with V’O2 peak < 10.4 ml/min/kg have a 50% risk of early death at 1 year and 
85% at 2 years (Wensel et al., 2002). Since CPET is not always available, field walking tests 
have been utilized to assess the degree of exercise intolerance in PAH (Steel, 1996). The 
degree of exercise impairment is judged by the measurement of distance covered during a 
fixed time period. The six minute walking test (6MWT), in which patients are free to choose 
the most convenient walking speed, is the most popular walking test (American Thoracic 
Society [ATS], 2002). The distance achieved in the 6MWT has been used as a primary 
endpoint in most randomised controlled trials of modern PAH therapies (Galiè et al., 2002). 
The 6MWT has good reproducibility and some studies have demonstrated a significant 
correlation between the 6MWT distance and peak oxygen uptake (V’O2 peak) measured 
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during standard incremental protocols (Myamoto et al., 2000). Walk distance and oxygen 
desaturation during 6MWT in patients with PAH relate well to V’O2 peak and appear to 
have a prognostic value (Myamoto et al., 2000; Paciocco et al., 2001). Unexplained dyspnea 
on exertion is the main symptom in the early stages of PAH and causes exercise intolerance. 
In PAH exercise intolerance correlates with the severity of the disease (Sun et al., 2002). 
Furthermore, the reduction of pulmonary vascular resistance and/or pulmonary arterial 
pressure with treatment (see below) is paralleled by changes in WHO FC and improvement 
in dyspnea on exertion as measured by the 6MWT. 
4. Management of dyspnea in pulmonary hypertension 
Treatment is determined by whether the pulmonary hypertension is arterial, venous, 
hypoxic, or thromboembolic and is first directed to the primary cause. Since pulmonary 
venous hypertension (Group 2) is synonymous with congestive heart failure, therapy of 
dyspnea aims to optimize left ventricular function through use of diuretics, beta blockers, 
and ACE inhibitors, and where relevant repair/replace dysfunctional heart valves. 
Similarly, in patients with lung disease and/or hypoxia (Group 3) therapy of dyspnea is 
usually directed at the underlying cause and correction of hypoxia. 
PAH (Group 1) has no underlying cardiac or respiratory cause and most often is associated 
with scleroderma or idiopathic. While lifestyle changes, digoxin, diuretics, oral 
anticoagulants, and oxygen therapy were long considered appropriate treatments for PAH-
associated dyspnea, these have never been proven to be beneficial in a randomized, 
prospective manner. As there is currently no cure, therapy of dyspnea in PAH is targeted at 
symptom control with the aim being to ease dyspneic symptoms thereby allowing patients 
to become more active, and to use treatments to reduce pulmonary vascular resistance and 
pressures and thereby slow disease progression.  
As outlined in subsequent sections, four major classes of medications are available for 
treatment of PAH-associated dyspnea (Fig. 1) (Humbert et al., 2004b). Calcium channel 
blockers reduce contractility of pulmonary arterial smooth muscle thereby reducing 
pulmonary vascular resistance. Prostacyclin analogues induce pulmonary vasodilation by 
supplementing inadequate endothelial prostacyclin caused by under-activity of endothelial 
prostacyclin synthase. Endothelin receptor antagonists block the vasoconstrictor effects of 
endothelin on pulmonary smooth muscle. Phosphodiesterase 5 (PDE5) inhibitors promote 
the vasodilation activity of the nitric oxide pathway by reducing conversion of cyclic 
guanylate monophosphate (a nitric oxide second messenger) to 5′-guanylate 
monophosphate (an inactive product). By reducing pulmonary arterial pressures and 
resistance, these treatments reduce dyspnea and improve exercise tolerance in patients with 
PAH. 
4.1 Calcium channel blockers 
High-dose calcium channel blockers only showed benefit for symptom relief in about 10% of 
patients with idiopathic PAH, who achieved reduction in their mean pulmonary arterial 
pressure and pulmonary vascular resistance by > 20% as measured by Swan-Ganz 
catheterization during acute vasodilator challenge. In the absence of measurable 
improvement in pulmonary arterial pressure, calcium channel blockers are not indicated. 
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Fig. 1. Therapeutic Targets for Pulmonary Arterial Hypertension 
Three major pathways involved in abnormal proliferation and contraction of the smooth-
muscle cells of the pulmonary artery in patients with pulmonary arterial hypertension are 
shown. These pathways correspond to important therapeutic targets in this condition and 
play a role in determining which of four classes of drugs -- endothelin-receptor antagonists, 
nitric oxide, PDE5 inhibitors, and prostacyclin derivatives -- will be used. At the top of the 
figure, a transverse section of a small pulmonary artery (<500 μm in diameter) from a 
patient with severe pulmonary arterial hypertension shows intimal proliferation and 
marked medial hypertrophy. Dysfunctional pulmonary-artery endothelial cells (blue) have 
decreased production of prostacyclin and endogenous nitric oxide, with an increased 
production of endothelin-1 -- a condition promoting vasoconstriction and proliferation of 
smooth-muscle cells in the pulmonary arteries (red). Therapies interfere with specific targets 
in smooth-muscle cells in the pulmonary arteries. In addition to their actions on smooth-
muscle cells, prostacyclin derivatives and nitric oxide have several other properties, 
including antiplatelet effects. Plus signs denote an increase in the intracellular concentration; 
minus signs blockage of a receptor, inhibition of an enzyme, or a decrease in the 
intracellular concentration; and cGMP cyclic guanosine monophosphate. 
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The criteria for vasoreactivity have recently changed. Only patients whose mean pulmonary 
artery pressure falls by > 10 mm Hg to < 40 mm Hg with an unchanged or increased cardiac 
output when challenged with adenosine, epoprostenol, or nitric oxideare considered 
“vasoreactive”. Of these, only 50% may have sustained response to calcium channel blockers 
(Rich & Brundage, 1987; Sitbon et al., 2005) and can be treated with dihydropiridine calcium 
channel blockers (i.e. nifedipine, felodipine or amlodipine) or diltiazem. Verapamil is 
contraindicated because of its negative inotropic effect. 
4.2 Prostacyclin analogues 
Prostacyclin is a potent pulmonary vasodilator and inhibits platelet aggregation. It is a 
metabolite of arachidonic acid produced in the normal vascular endothelium. Reduced 
expression of prostacyclin synthase in patients with PAH causes prostacyclin deficiency. 
Epoprostenol is a potent, short-acting prostacyclin analogue that induces pulmonary 
vasodilation and is approved for treatment of patients with PAH in WHO FC III or IV. 
Epoprostenol is administered by continuous intravenous infusion through an indwelling 
central line. Unfortunately, it is expensive, inconvenient (patients need to carry a continuous 
infusion pump) and has significant dose-dependent adverse effects including flushing, 
headache, jaw and lower extremity muscular pain, diarrhea, nausea, and rash. Patients with 
PAH may live at distance from the nearest tertiary care facility and a well-established 
setting for ensuring continuous supply and supervision is critical, as sudden interruption of 
the epoprostenol infusion may cause rebound severe PAH and death. Despite the side 
effects and inconveniences with administration, epoprostenol has solid clinical evidence of 
efficacy in PAH. It has been shown to reduce dyspnea, improve exercise capacity, quality of 
life and survival in patients with PAH (Badesch et al., 2000; Barst et al., 1996; McLaughlin et 
al., 2002; Sitbon et al., 2002). Three-year survival of patients with PAH treated with 
epoprostenol was 63% (McLaughlin et al., 2002; Sitbon et al., 2002). Most patients 
experienced optimal benefit from epoprostenol at a stable dose of 25 to 40 ng/kg per 
minute, after incremental increases over the course of 6 -12 months from an initial dosage of 
2 to 6 ng/kg per minute.  
Treprostinil is a prostacyclin analogue that is stable at room temperature and has a longer 
half-life than epoprostenol (3-4 hours). This allows it to be given intravenously or via a small 
subcutaneous catheter with a continuous pump. Treatment by either route improves the 
6MWT distance in patients with PAH in WHO FC III or IV (Simonneau et al., 2002; Tapson 
et al., 2006). Three-year survival of patients with idiopathic PAH treated with subcutaneous 
treprostinil monotherapy has been reported as 71% (Barst et al., 2006a). Whilst short-term 
efficacy of intravenous treprostinil may equal epoprostenol; comparative survival data are 
lacking. The adverse effect profile of treprostinil is similar to epoprostenol. Frequent, severe 
pain at the site of infusion may limit the treprostinil dose that can be administered 
subcutaneously. This limitation may reduce treprostinil's efficacy because the effect on 
6MWT distance is dose-dependent, and higher doses may require intravenous 
administration. Other clinical trials of treprostinil inhaled and oral formulations are 
ongoing. Some patients treated with epoprostenol may be switched to intravenous 
treprostinil with maintenance of 6MWT distance; although a larger dose of treprostinil is 
required (Gomberg-Maitland et al., 2005). 
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Iloprost is an inhaled prostacyclin analogue that was shown to improve dyspnea, exercise 
capacity and hemodynamics in patients with PAH. In a randomized, placebo-controlled, 12-
week study, iloprost produced a placebo-corrected increase in 6MWT distance of 36 m in 
207 patients with symptomatic idiopathic PAH, PAH associated with connective tissue 
disease or appetite suppressants, or pulmonary hypertension related to inoperable chronic 
thromboembolic disease (Olschewski et al., 2002). Long-term maintenance of improved 
exercise capacity and hemodynamics was observed with iloprost use (Hoeper et al., 2000). 
Adverse effects of iloprost are similar to other prostacyclin analogues and include flushing, 
headache, and cough. A major downside for patients is that iloprost’s short duration of 
action necessitates frequent 10-minute inhalations, 6 to 9 times per day.  
4.3 Endothelin receptor antagonists (ERA) 
By binding to endothelin receptors A and B, endothelin-1 triggers pulmonary 
vasoconstriction and stimulates vascular smooth muscle and fibroblast proliferation. 
Endothelin-1 levels are increased in PAH, and correlate with disease severity, suggesting 
that blockade of endothelin-1 should have beneficial effects. Bosentan is an orally-active, 
dual ERA that improves exercise capacity, quality of life, hemodynamics, and time to 
clinical worsening in PAH (Channick et al., 2001; Rubin et al., 2002). Two-year survival of 
patients with idiopathic PAH in whom bosentan was used as first-line therapy was 87% 
(McLaughlin et al., 2005; Provencher et al., 2006). Bosentan is currently approved for 
treatment of PAH patients in WHO FC III or IV. Adverse effects of bosentan include 
flushing, edema, nasal congestion, mild anemia, and teratogenicity. Dose-dependent 
elevation of liver transaminases occurs in about 10% of patients on bosentan, requiring 
monthly monitoring of liver function.  
Ambrisentan and sitaxentan are ERA with relative selectivity for the endothelin receptor 
subtype A. Treatment with sitaxentan was efficacious for patients with PAH with low 
incidence of liver toxicity in initial reports (Barst et al., 2006b; Benza et al., 2008). However, it 
was recently removed from the market due to case reports of severe hepatitis and liver 
toxicity. Ambrisentan is another ERA with safer liver toxicity profile. It has been shown to 
improve symptoms, exercise capacity, and hemodynamics (Galiè et al., 2005a). Adverse 
effects of ambrisentan include flushing, edema, nasal congestion, and teratogenicity.  
Although associated with a low incidence of liver enzyme elevations, monthly liver function 
monitoring is still required (McGoon et al., 2009). 
4.4 Phosphodiesterase 5 Inhibitors 
Sildenafil, originally commercialized for erectile dysfunction, is a potent, highly specific 
inhibitor of PDE5 that has been shown to improve symptoms and functional capacity in 
PAH patients (Galiè et al., 2005b). Adverse effects associated with sildenafil include 
headache, flushing, dyspepsia, nasal congestion, and epistaxis. Nitrates are contraindicated 
in patients taking PDE5 inhibitors because the additive effects of the drugs can cause life-
threatening hypotension.  
Tadalafil, a long-acting PDE5 inhibitor, is the most recent oral agent for treatment of PAH 
(Rosenzweig, 2010). The Pulmonary Arterial Hypertension and Response to Tadalafil 
(PHIRST) clinical trial examined the efficacy and tolerability of tadalafil for the treatment of 
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PAH over a period of 16 weeks (Galiè et al., 2009a). Tadalafil 40 mg showed significant 
improvement over placebo for six of eight SF-36 domains and EQ-5D index scores. Also, the 
tadalafil 40-mg group showed significant improvement over placebo on the 6MWT distance 
(p < 0.001), but no clear relationship was found between 6MWT distance and health-related 
quality of life (HRQoL). Results suggest that tadalafil may significantly improve HRQoL 
and exercise capacity in patients with PAH. 
4.5 Combination treatments 
Combinations of disease-modifying agents of various classes seems a logical next step in 
PAH management and is becoming standard care in many PAH centres. Clinical trial 
evidence for combination therapy is encouraging (Humbert et al., 2004a; McLaughlin et al., 
2006; O’Callaghan & Gaine, 2007; Simonneau et al., 2008). The relatively small BREATHE-2 
study (Humbert et al., 2004a) showed a trend to haemodynamic improvement with 
combination epoprostenol-bosentan as compared to epoprostenol alone. The STEP-1 study 
(Simonneau et al., 2008) addressed the safety and efficacy of 12 weeks therapy with inhaled 
iloprost plus bosentan and reported a non-significant increase of 26 m in the post-inhalation 
6MWT distance (p=0.051). There was no improvement in pre-inhalation haemodynamics in 
the iloprost group after 12 weeks of treatment, but time to clinical worsening was 
significantly prolonged in the iloprost group (0 events versus 5 events in the placebo group; 
p = 0.02). In contrast, the COMBI trial which also studied the benefits of inhaled iloprost 
added to bosentan, was stopped prematurely after a planned interim analysis failed to show 
an effect on 6MWT distance or time to clinical worsening (Hoeper et al., 2006). The 
TRIUMPH trial studied the effects of inhaled treprostinil in patients already treated with 
bosentan or sildenafil (McLaughlin et al., 2010). The primary end-point, change in 6MWT 
distance at peak exposure, improved by 20 m compared with placebo (p<0.0006). At trough 
exposure, i.e. after >4 hours post-inhalation, the difference was 14 m in favour of the 
treprostinil group (p<0.01). There were no significant differences in Borg dyspnea index, 
functional class and time to clinical worsening. The PACES trial addressed the effects of 
adding sildenafil to epoprostenol in 267 patients with PAH (Simonneau et al., 2008) and 
showed significant improvements after 12 weeks in 6MWT distance and time to clinical 
worsening.  
Additional data are available for the combination of ERA and PDE5 inhibitors. In the 
subgroup of patients enrolled in the EARLY study (Galiè et al., 2008) (bosentan in WHO FC 
II PAH patients already on treatment with sildenafil), the haemodynamic effect of the 
addition of bosentan was comparable with that achieved in patients without background 
sildenafil treatment. A pharmacokinetic interaction has been described between bosentan 
and sildenafil, which act as inducers or inhibitors of cytochrome P450 CYP3A4, respectively. 
The co-administration of both results in a decline of sildenafil and increase in bosentan 
plasma levels (Paul et al., 2005). So far there is no indication that these interactions are 
associated with reduced safety (Humbert et al., 2007), but whether the clinical efficacy of 
sildenafil is significantly reduced is still controversial. No pharmacokinetic interactions have 
been reported between sildenafil and the two other available ERAs, sitaxentan and 
ambrisentan. In the PHIRST study (Galiè et al., 2009a) the combination of tadalafil and 
bosentan resulted in an improvement of exercise capacity of borderline statistical 
significance.  
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Fig. 2. Treatment algorithm for PAH-associated dyspnea 
Evidence-based treatment algorithm for treatment of dyspnea caused by pulmonary 
arterial hypertension (group 1 patients only). APAH: associated pulmonary arterial 
hypertension; BAS: balloon atrial septostomy; CCB: calcium channel blocker;  
ERA: endothelin receptor antagonist; IPAH: idiopathic pulmonary arterial hypertension; 
PAH: pulmonary arterial hypertension; PDE-5 I: phosphodiesterase type-5 inhibitor;  
s.c.: subcutaneously; WHO-FC: World Health Organization functional class. #: to maintain 
arterial blood O2 pressure >8 kPa (60 mmHg); ¶: under regulatory review in the European 
Union; +: IIa-C for WHO-FC II. 
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In summary, whether the response to monotherapy is sufficient or not can only be decided 
on an individual basis. Combination therapy is recommended for PAH patients not 
responding adequately to monotherapy and ideally should be instituted by experienced 
centres (Fig. 2). 
5. Palliative and supportive treatments for residual dyspnea in treated 
progressive pulmonary hypertension 
Since PAH is not a curable disease, many patients inevitably progress to WHO-FC IV with 
severe dyspnea. This necessitates additional palliative and supportive treatments. Exercise 
training, atrial septostomy and opioids are some of the interventions that may have a role in 
improving symptoms and exercise tolerance in patients with progressive PAH. 
Exercise in the form of respiratory and physical training appears efficacious as part of the 
management of PAH. When superimposed on an optimal stable drug regimen, 15 weeks of 
respiratory and physical training led to an average increase of 111 m in 6MWT distance, in 
addition to improvements in other measures of exercise tolerance and quality of life 
(Mereles et al., 2006). This is a major benefit when put in the perspective of expensive PAH 
medications that may deliver more modest 20-40 m improvements in 6MWT distance. 
Atrial septostomy performed by graded balloon dilatation may be suitable for selected 
patients with severe PAH. In patients with medically treated severe progressive PAH, atrial 
septostomy improved clinical symptoms and dyspnea, cardiac index, exercise endurance 
and systemic oxygen transport (Reichenberger et al., 2003; Sandoval et al., 1998). 
Transplantation is an important option for selected PAH patients. Up to 25% of patients with 
PAH fail to improve on disease-specific therapy and the prognosis of patients who remain in 
WHO FC III or IV is poor. International guidelines to aid referral and listing have been 
published by the International Society for Heart and Lung Transplantation (Orens et al., 
2006). Both heart–lung and double-lung transplantation have been performed for PAH and 
each centre has developed its own strategy for the choice of the type of transplantation in the 
individual patient. However, due to the shortage of donor organs, most patients are 
considered for double-lung transplantation. While right ventricular afterload is immediately 
reduced after double-lung transplantation, right ventricular systolic and left ventricular 
diastolic functions do not improve immediately and hemodynamic instability is a common 
problem in the early post-operative period. The overall 5-year survival following 
transplantation for PAH is 45–50%, with evidence of sustained improvement in dyspnea and 
quality of life (Trulock et al., 2006). 
In parallel with attempts to treat the underlying pathology causing dyspnea, the sensation 
of breathlessness itself must be ameliorated. For many patients there comes a point when 
there are no further identifiable reversible components of PAH and the treatment focus 
needs to move to reducing the subjective sensation of breathlessness (Davis, 1994). Like 
pain, dyspnea has a sensory and an affective dimension. Therefore, treatment strategies in 
dyspnea should be similar to those used in pain. Recent neuroimaging studies suggest that 
neural pathways involved in pain and dyspnea sensation may be shared and, therefore, 
similar neurophysiological and psychological approaches used to understand and manage 
pain can be applied to dyspnea (Nishino, 2011). Previous randomised controlled trials have 
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reported the effectiveness of sustained-release morphine in patients with refractory 
dyspnea, including those with severe COPD (Abernethy et al., 2003; Poole et al., 1998) and 
chronic heart failure (Johnson et al., 2002). Currently there is no data on use of opioids to 
relieve dyspnea in patients with progressive advanced PAH and clinical trials are on-going. 
Effective and predictive treatment of dyspnea remains elusive and a better understanding of 
the pathophysiology and neurophysiology of dyspnea may lead to more effective 
treatments. 
6. Conclusion 
Etiological diagnosis and assessment of pulmonary hypertension WHO functional class is 
critical for management. Despite recent advances in understanding and treatment of PAH it 
remains a progressive and incurable disease, with dyspnea and exercise intolerance being 
the major causes of distress to sufferers. More effective palliation of dyspnea in patients with 
PAH depends on better understanding of it’s mechanisms. More randomised clinical trial 
evidence on combination and palliative treatments is needed to improve management of 
dyspnea in patients with advanced PAH. 
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